Depomed — Investor Presentation (January 2012)
29 slides from Depomed's investor presentation, Jan 9, 2012
Slide 1: An Emerging Specialty Pharmaceutical Leader
Confidential Information January 9, 2012 An Emerging Specialty Pharmaceutical Leader
Slide 2: Note on Forward-Looking Statements
Statements made in this presentation that are not historical facts are forward-looking statements that involve risks and uncertainties. The inclusion of forward-looking statements, including those related to our commercialization plans for GraliseTM, our clinical development programs, potential bene
Slide 3: Depomed Investment Opportunity
Depomed Investment Opportunity Establishing leadership in the CNS specialty pharmaceutical sector Building a successful, profitable, product-focused pharmaceutical business Delivering sustainable value to stakeholders: patients/families, physicians, providers, payers, shareholders, employees Strong
Slide 4: 3 in 3 Business Model: 3-Pronged Growth Strategy
3 in 3 Business Model: 3-Pronged Growth Strategy Grow top line Achieve commercial success of branded marketed products Gralise in PHN: cornerstone of CNS-focused franchise, with realizable $100 million+ market potential Grow bottom line “Cash cow” Glumetza strategy: restructured Santarus agreement p
Slide 5: 3-Year Plan to Sustained Profitability and Shareholder ROI: 2011
3-Year Plan to Sustained Profitability and Shareholder ROI 2011: Setting the Stage Pivotal year assembling the building blocks of CNS franchise business Reacquired, successfully launched flagship product Gralise with pharma-quality commercial implementation Early indicators: market uptake ramping ni
Slide 6: 2012: Execution
2012: Execution Grow Gralise market penetration – keys to growth Pain specialists Neurologists Managed care Deals build on track record of > $230 million cash received from in non-dilutive deals since 2006 Grow CNS franchise Opportunistically acquire selective, financially sound assets Depomed, Inc.
Slide 7: 2013: Aggressive Growth
2013: Aggressive Growth Establish Gralise year-end run rate of $100+ million Glumetza contributing potentially $40+ million to bottom line Selective acquisition or development of portfolio assets with immediate or near-term revenue potential Meaningful valuation and EPS growth: reaching cash-positiv
Slide 8: 2014: Leadership
2014: Leadership Depomed established as a successful, profitable mid-sized specialty pharmaceutical company Expanded portfolio of assets with significant growth potential, driving sales and profitability Continue to deliver significant shareholder value Depomed, Inc. | January 9, 2012 | Page 8
Slide 9: A Potential New Standard of Care in PHN
A Potential New Standard of Care in PHN Large market opportunity Clinical differentiation; unmet medical need Pharma-quality pre-launch and launch (October 2011) 164 rep sales force targeting all customer segments: physicians, payors, pharmacies Post-launch monitoring and adjustments as needed Depom
Slide 10: Large Market Opportunity
Large Market Opportunity Gabapentin + Lyrica > $2 billion market ~38 million prescriptions annually in the US US gross sales for target market ($ billions) Depomed, Inc. | January 9, 2012 | Page 10
Slide 11: Clinically Differentiated
Clinically Differentiated Effective 24-hour pain control Significant and lasting improvement in pain scores in clinical studies Once-daily dosing with an evening meal Patented polymer technology allows for peak plasma levels during the night and low rates of side effects during the day Favorable tol
Slide 12: Effective, 24-Hour PHN Pain Control with Once-Daily Gabapentin
Effective, 24-Hour PHN Pain Control with Once-Daily Gabapentin Gralise (1800mg) Neurontin (1800-2400mg) Lyrica (15-300mg) Reduction in Pain Score(1) -2.4 -2.2 to -2.3 -1.8 to -2.2 Dosing 1x daily dosing 3 to 4x daily dosing 2 to 3x daily dosing Dizziness 10.9% 31% - 33% 12% - 28% Somnolence 4.5% 17%
Slide 13: Starter Pack Simplifies Titration for Doctors and Patients
Starter Pack Simplifies Titration for Doctors and Patients The 30-Day Starter “G-Pack” guides patients through the 2-week titration period and 2 weeks of therapy at the recommended dose of 1800 mg. Comes with clear instructions for patients on when to increase the Gralise dose. Depomed, Inc. | Janua
Slide 14: Market Addressable with Sales Reps
Market Addressable with 164 Sales Reps Decile 3-10 Neurologists, Pain Specialists; Decile 5-10 PCPs; further segmented based on behavioral characteristics and treatment patterns. Written by target prescribers. Addressable Rx Market: Gabapentin and Lyrica ~23 million TRx(2) Neurologists, Pain Special
Slide 15: Positive Physician and Managed Care Reaction
Physician Reaction to Gralise “I now have a once-a-day preparation of the drug that I’ve been using as a mainstay – sounds great. Biggest problem with gabapentin is it’s three times a day, with the side effects, and suddenly, we’ve got it once a day...” PCP Interview August 2011 KOL Reaction to Gral
Slide 16: Full Complement of Marketing Materials and Support Initiatives for Launch
Full Complement of Marketing Materials and Support Initiatives for Launch iPad Visual Aid 30-day samples 15-day samples (11/15) File Card Business Card Holder GRALISE Absorption Video Co-Pay Assistance Card Annotated PI Prior Auth. Hotline Depomed, Inc. | January 9, 2012 | Page 16
Slide 17: Well-Stocked and Launched with Broad Managed Care Coverage
Coverage as of 12/31/2011 8 out of 10 lives have access to Gralise 91% of Commercial Plans have Gralise at Tier 3 or better Managed Care Team Actively Engaged with All Payer Types Government TriCare (9MM lives): $12 co-pay NY Medicaid (5MM beneficiaries) and TX Medicaid (3.2MM beneficiaries): unrest
Slide 18: Solid Growth to Annualized Gross Revenue Run Rate > $5M at Week 10
Solid Growth to Annualized Gross Revenue Run Rate > $5M at Week 10 Depomed, Inc. | January 9, 2012 | Page 18 $3.4 $3.9 $4.9 $5.2 $- $1.0 M $2.0 M $3.0 M $4.0 M $5.0 M $6.0 M 12/2/2011 12/9/2011 12/16/2011 12/23/2011 Annualized Gross Revenue (prescription basis) Week Ending
Slide 19: TRx Breakdown Shows Strong Specialist Uptake
TRx Breakdown Shows Strong Specialist Uptake Depomed, Inc. | January 9, 2012 | Page 19 Gralise TRx by Specialty TRx by Payment Type (November 2011)
Slide 20: Taking Share From Others
Taking Share From Others Depomed, Inc. | January 9, 2012 | Page 20 Gralise Source of Business Patients switching to Gralise were taking: 11% of Gralise patients are refills (continuing therapy) 57% of Gralise patients are switching from an existing therapy (either a gabapentinoid, Lidoderm or Cymbal
Slide 21: More than 1000 Unique Prescribers
More than 1000 Unique Prescribers at Week 10 Depomed, Inc. | Private & Confidential | 19 Active Prescriber: Prescribing Gralise >0 times in the most recent rolling 4 week period Unique Prescriber: Prescribing Gralise >0 times since launch Source: IMS through 12/16/2011, retail & mail order
Slide 22: Glumetza: Bottom-Line Growth Driver
Glumetza: Bottom-Line Growth Driver Santarus Glumetza #1 product (>50% of total revenue) eVoucher program (= $10 co-pay) initiated in September 2011 Weekly Glumetza Rx and number of tablets up by 17% Adding 40 sales rep in January (150 reps total) Depomed Cash cow product with significant growth pot
Slide 23: Acuform Technology Platform: Highly Monetizable Asset
Acuform Gastric Retention Technology is a continuing source of revenue and cash: License Fees Milestones Royalties Five Acuform technology licenses — potential future milestones (2011 – 2015+) and royalties (2012+) Strengthens bottom line with limited expenditure of resources Acuform® Technology Pla
Slide 24: Strong Recurring Revenue from Acuform Technology Deals
Strong Recurring Revenue from Acuform Technology Deals Janumet XR -- Januvia (sitagliptin) / metformin XR combination NDA approval pending Regulatory filings ex-US in process Modest royalty upon market launch SGLT2 inhibitor / metformin XR combination Additional milestone and royalties Boehringer co
Slide 25: Strong IP/Regulatory Protection for Marketed Products
Strong IP/Regulatory Protection for Marketed Products Glumetza 500mg - Depomed formulation 4 Orange Book listed technology patents expiring 2016 - 2021 1000mg - Valeant formulation 2 Orange Book listed patents listed expiring 2021 and 2025 Gralise Depomed proprietary formulation 6 Orange Book listed
Slide 26: Serada for Menopausal Hot Flashes
Serada® for Menopausal Hot Flashes Breeze 3 top line data announced October 2011 Three of four co-primary endpoints met Two key secondary endpoints not met All met on ANCOVA analysis Further evaluation ongoing Analyzing Breeze 3 data Compiling combined data from Breeze 3 and two prior trials Plan to
Slide 27: Strong Balance Sheet
Cash position: $154.2 million on 9/30/2011 No debt Strong Balance Sheet Depomed, Inc. | January 9, 2012 | Page 27
Slide 28: Depomed Today
Depomed Today Commercially attractive, new product launch successfully underway Solid base of business with significant growth potential Strong balance sheet Strong and defensible IP position Multiple value-creating milestones upcoming Experienced, proven leadership team aggressively pursuing realis
Slide 29: An Emerging Specialty Pharmaceutical Leader
Confidential Information January 9, 2012 An Emerging Specialty Pharmaceutical Leader